118 related articles for article (PubMed ID: 24158386)
21. Gemcitabine, vinorelbine and dexamethasone: A safe and effective regimen for treatment of relapsed/refractory hodgkin's lymphoma.
Ganesan P; Mehra N; Joel A; Radhakrishnan V; Dhanushkodi M; Perumal Kalayarasi J; Kannan K; Ganesan TS; Sagar TG
Leuk Res; 2019 Sep; 84():106188. PubMed ID: 31325732
[TBL] [Abstract][Full Text] [Related]
22. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma.
Kuruvilla J; Nagy T; Pintilie M; Tsang R; Keating A; Crump M
Cancer; 2006 Jan; 106(2):353-60. PubMed ID: 16329112
[TBL] [Abstract][Full Text] [Related]
23. Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma.
Yim KL; Ashley S
Med Oncol; 2012 Dec; 29(5):3535-9. PubMed ID: 22825684
[TBL] [Abstract][Full Text] [Related]
24. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
[TBL] [Abstract][Full Text] [Related]
25. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.
Oki Y; Pro B; Fayad LE; Romaguera J; Samaniego F; Hagemeister F; Neelapu S; McLaughlin P; Goy A; Younes A
Cancer; 2008 Feb; 112(4):831-6. PubMed ID: 18085611
[TBL] [Abstract][Full Text] [Related]
26. CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.
Gleeson M; Peckitt C; To YM; Edwards L; Oates J; Wotherspoon A; Attygalle AD; Zerizer I; Sharma B; Chua S; Begum R; Chau I; Johnson P; Ardeshna KM; Hawkes EA; Macheta MP; Collins GP; Radford J; Forbes A; Hart A; Montoto S; McKay P; Benstead K; Morley N; Kalakonda N; Hasan Y; Turner D; Cunningham D
Lancet Haematol; 2018 May; 5(5):e190-e200. PubMed ID: 29703335
[TBL] [Abstract][Full Text] [Related]
27. Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma.
Moccia AA; Hitz F; Hoskins P; Klasa R; Power MM; Savage KJ; Shenkier T; Shepherd JD; Slack GW; Song KW; Gascoyne RD; Connors JM; Sehn LH
Leuk Lymphoma; 2017 Feb; 58(2):324-332. PubMed ID: 27347845
[TBL] [Abstract][Full Text] [Related]
28. Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma.
Bai B; Huang HQ; Cai QQ; Wang XX; Cai QC; Lin ZX; Gao Y; Xia Y; Bu Q; Guo Y
Med Oncol; 2013 Mar; 30(1):350. PubMed ID: 23329307
[TBL] [Abstract][Full Text] [Related]
29. Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant.
Czyz A; Romejko-Jarosinska J; Knopinska-Posluszny W; Nowicki A; Lojko-Dankowska A; Gil L; Dytfeld D; Walewski J; Hellmann A; Komarnicki M
Leuk Lymphoma; 2013 May; 54(5):973-8. PubMed ID: 23025342
[TBL] [Abstract][Full Text] [Related]
30. B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).
Balzarotti M; Brusamolino E; Angelucci E; Carella AM; Vitolo U; Russo E; Congiu A; Gotti M; Massidda S; Botto B; Annechini G; Spina M; Re A; Zilioli VR; Merli F; Salvi F; Stelitano C; Bonfichi M; Rodari M; Murru R; Magagnoli M; Anastasia A; Mazza R; Giordano L; Santoro A
Leuk Lymphoma; 2016 Oct; 57(10):2375-81. PubMed ID: 26879066
[TBL] [Abstract][Full Text] [Related]
31. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Moskowitz AJ; Shah G; Schöder H; Ganesan N; Drill E; Hancock H; Davey T; Perez L; Ryu S; Sohail S; Santarosa A; Galasso N; Neuman R; Liotta B; Blouin W; Kumar A; Lahoud O; Batlevi CL; Hamlin P; Straus DJ; Rodriguez-Rivera I; Owens C; Caron P; Intlekofer AM; Hamilton A; Horwitz SM; Falchi L; Joffe E; Johnson W; Lee C; Palomba ML; Noy A; Matasar MJ; Pongas G; Salles G; Vardhana S; Sanin BW; von Keudell G; Yahalom J; Dogan A; Zelenetz AD; Moskowitz CH
J Clin Oncol; 2021 Oct; 39(28):3109-3117. PubMed ID: 34170745
[TBL] [Abstract][Full Text] [Related]
32. Lomustine, cytarabine, cyclophosphamide, etoposide - An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors.
Gupta A; Gokarn A; Rajamanickam D; Punatar S; Thippeswamy R; Mathew L; Bagal B; Kannan S; Khattry N
J Cancer Res Ther; 2018; 14(5):926-933. PubMed ID: 30197327
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience.
Batgi H; Başcı S; Dal MS; Kızıl Çakar M; Uncu Ulu B; Yiğenoğlu TN; Özcan N; Kılınç A; Merdin A; Yıldız J; Bakırtaş M; Şahin D; Darçın T; İskender D; Baysal NA; Altuntaş F
Turk J Med Sci; 2021 Apr; 51(2):685-692. PubMed ID: 33237657
[TBL] [Abstract][Full Text] [Related]
34. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.
Josting A; Rudolph C; Reiser M; Mapara M; Sieber M; Kirchner HH; Dörken B; Hossfeld DK; Diehl V; Engert A;
Ann Oncol; 2002 Oct; 13(10):1628-35. PubMed ID: 12377653
[TBL] [Abstract][Full Text] [Related]
35. ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma.
Labrador J; Cabrero-Calvo M; Pérez-López E; Mateos MV; Vázquez L; Caballero MD; García-Sanz R
Ann Hematol; 2014 Oct; 93(10):1745-53. PubMed ID: 24863692
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
Fan Y; Huang ZY; Luo LH; Yu HF
Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
[TBL] [Abstract][Full Text] [Related]
37. Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma.
Hou Y; Wang HQ; Ba Y
Med Oncol; 2012 Dec; 29(4):2409-16. PubMed ID: 22476761
[TBL] [Abstract][Full Text] [Related]
38. High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin's lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy.
Rauf MS; Maghfoor I; Elhassan TA; Akhtar S
Med Oncol; 2015 Jan; 32(1):388. PubMed ID: 25429839
[TBL] [Abstract][Full Text] [Related]
39. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.
Martoni A; Marino A; Sperandi F; Giaquinta S; Di Fabio F; Melotti B; Guaraldi M; Palomba G; Preti P; Petralia A; Artioli F; Picece V; Farris A; Mantovani L
Eur J Cancer; 2005 Jan; 41(1):81-92. PubMed ID: 15617993
[TBL] [Abstract][Full Text] [Related]
40. Gemcitabine, etoposide, cisplatin, and dexamethasone in patients with refractory or relapsed non-Hodgkin's lymphoma.
Kim KH; Joo YD; Sohn CH; Shin HJ; Chung JS; Cho GJ; Shin SH; Kim YS; Lee WS
Korean J Intern Med; 2009 Mar; 24(1):37-42. PubMed ID: 19270480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
